Shares of Mylan N.V. (MYL) traded 0.61 points or 1.6% higher at $38.66.The total intraday money flow for the shares came in at a disappointing $(-7.61) million. The total upticks amounted to $31.89 million and the total downticks were approximately $39.51 million, with the up/down ratio of 0.81. On a different note, the shares have seen 5.46% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $4.63 million in upticks and an outflow of $12.4 million in downticks. The up/down ratio for the block was found to be 0.37. The net money flow for the block transaction was $(-7.76) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Mylan N.V. rose by 5.98% in the last five trading days and 1.34% for the last 4 weeks. Mylan N.V. is up 5.92% in the last 3-month period. Year-to-Date the stock performance stands at 1.34%. Mylan N.V. (NASDAQ:MYL) rose 1.6% or 0.61 points on Wednesday and made its way into the gainers of the day. After trading began at $38.68 the stock was seen hitting $38.75 as a peak level and $38.07 as the lowest level. The stock ended up at $38.66. The daily volume was measured at 5,917,169 shares. The 52-week high of the share price is $53.21 and the 52-week low is $33.6. The company has a market cap of $20,687 million.
Company has reported several Insider transactions to the SEC, on Aug 11, 2016, Heather M Bresch (Chief Executive Officer) sold 100,200 shares at 50.00 per share price.On Jun 6, 2016, Joseph C Md Maroon (director) purchased 1,670 shares at 44.95 per share price.On May 25, 2016, Robert J Cindrich (director) purchased 1,190 shares at 42.47 per share price.
Mylan NV Last issued its quarterly earnings results on Nov 9, 2016. The company reported $1.38 EPS for the quarter, missing the analyst consensus estimate by $ -0.08. Analyst had a consensus of $1.46. The company had revenue of $3057.10 million for the quarter, compared to analysts expectations of $3146.07 million. The companys revenue was up 13.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.43 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Mylan NV was Downgraded by Citigroup to Neutral on Jan 5, 2017. Mylan NV was Reiterated by Mizuho on Nov 18, 2016 to Buy, Lowers Price Target to $ 47 from a previous price target of $49 .
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.